Health Care Delivery

Benjamin Garmezy, MD, explains what varying Nectin-4 expression means for treatment selection in bladder cancer and what trials are still needed.

Clesrovimab remained well tolerated through a second RSV season in infants at increased risk of severe RSV.

Urs Weber, MD, explains how multidisciplinary teams streamline biomarker testing and improve treatment planning in thoracic oncology.

Dry eye symptoms are often mischaracterized or overlooked due to low awareness, delaying diagnosis and treatment and hurting quality of life.

The Pharmacy Compounding Advisory Committee meets July 23-24 to discuss whether pharmacies may dispense BPC-157, TB-500, and 5 other peptides.

Trump said imported generic drugs will face no tariff for 2 years starting August 1, then a 100% rate in 2028 and 200% in 2029, extending his trade fight to the drugs most Americans actually take.

Urs Weber, MD, discusses why comprehensive NGS is critical and where community biomarker testing often falls short.

David Zhang, MD, discusses the limitations of polygenic risk scores and remaining barriers to their clinical use in idiopathic pulmonary fibrosis.

Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, BCOP, and bispecifics will bring another shift.

Diagnostic delays and access barriers continue to affect patients with MS, especially in under-resourced areas, World Brain Day highlights.

Reimbursement fixes, policy corrections, and expanded rural training could close dermatology's rural workforce gap, said Jane Grant-Kels, MD.

Cognitive rehabilitation significantly improved goal attainment and satisfaction in adults with long COVID-related cognitive impairment.

Kanita Bourne, LCSW, discusses how implicit bias, missed depression signs, and expanded doula access are shaping Black maternal health outcomes.

David Zhang, MD, discusses how real-world EHR and biobank data could advance polygenic risk scores for IPF diagnosis and risk prediction.

Paul Hahn, MD, says access and reimbursement, not innovation, are retina care’s biggest barriers and outlines where the field is headed next.

CRC treatment delays were linked to higher metastatic risk, but meaningful thresholds varied by treatment pathway, supporting tailored benchmarks.

US drug shortages rose to 227 in Q2 2026, led by a severe ifosfamide shortage.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, explains how GLP-1-based therapies are reshaping diabetes, obesity, and cardiometabolic care and what that means for coverage decisions.

Hepatitis B and C prevention programs improve detection, treatment, and liver outcomes, but screening, care access, and implementation gaps remain.

Emily Curran, MD, University of Cincinnati, calls for decentralized trials and stronger community-academic ties to widen ALL patient access.

A common, underdiagnosed genetic disorder, hereditary hemochromatosis is costly when caught late and simple to treat when caught early.

Designated teams, standardized SOPs, and scalable workflows are essential before a community practice's first bispecific dose.

Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 and SGLT2 inhibitors are used.

FTC settles with CVS Caremark over insulin pricing, projecting $8.5 billion in patient savings over 10 years and mandating rebate and access reforms.

Respiratory rehabilitation improved exercise capacity in patients with COPD with and without suspected pulmonary hypertension.